Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 11, 2025 70 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EPCORE FL-1 study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Woman with Strong Family History of Cancer Finally Gets Diagnosis After... November 4, 2020 Second Drug Targeting KRAS G12C Shows Benefit in Mutated Non-Small-Cell Lung... March 25, 2021 Building a Balanced Breakfast November 6, 2020 Child Cancer Patient And His Dad Have A Little Fun When... October 3, 2019 Load more HOT NEWS Access to Cancer Medicines and Clinical Trials Show Stark Variations Across... Rebuilding My Life After Cancer and Intensive Treatment: A Survivor’s Story Five Questions With…Francisco. Some People with Rectal Cancer Can Skip Radiation Before Surgery
